CBS 001
Alternative Names: Anti-LIGHT monoclonal antibody - Centessa Pharmaceuticals; Anti-TNFSF14-monoclonal-antibody - Centessa Pharmaceuticals; CBS-001Latest Information Update: 05 Oct 2023
At a glance
- Originator Capella BioScience
- Developer Capella BioScience; Centessa Pharmaceuticals
- Class Anti-inflammatories; Monoclonal antibodies
- Mechanism of Action Tumour necrosis factor ligand superfamily member 14 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Idiopathic pulmonary fibrosis; Inflammation
Most Recent Events
- 22 Aug 2023 Capella Bioscience and Centessa Pharmaceuticals terminate a phase I trial in Inflammation (In volunteers) in United Kingdom (IV), due to portfolio reprioritisation (NCT05323110)
- 30 Mar 2023 Suspended - Phase-I for Idiopathic pulmonary fibrosis (In volunteers) in United Kingdom (Parenteral)
- 30 Mar 2023 Suspended - Phase-I for Inflammation (In volunteers) in United Kingdom (IV)